ClinicalTrials.gg
Active, not recruitingNCT02016924Updated Apr 21, 2026

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

A Phase 2/3 interventional study of ATV and DRV in Acquired Immune Deficiency Syndrome (AIDS) and HIV Infections, sponsored by Gilead Sciences. Active, not recruiting at 23 sites in 7 countries. Open to participants aged 4 Weeks to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
133
Allocation
Non-randomized
Ages
4 Weeks to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing atazanavir in Acquired Immunodeficiency Syndrome — none open to participants now, 1 under way, 1 of them phase 3. atazanavir · Acquired Immunodeficiency Syndrome.

Enrollment
7th of 20
133 · median 63
Started
2014
with 1 other
Phase 2/3
Only one
of the 20
Registered
20th of 20
by date
Lead sponsor
3 of 20
Gilead Sciences

Among the 20 studies testing atazanavir in Acquired Immunodeficiency Syndrome, this one is the 7th largest by enrollment, is one of 2 that started in 2014, is the only one in phase 2/3, and was the 20th registered.

Acquired Immunodeficiency Syndrome

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

None of the 20 studies testing atazanavir in Acquired Immunodeficiency Syndrome is open now. The open studies under Acquired Immunodeficiency Syndrome, anywhere →

About atazanavir

atazanavir: first FDA approval 2003 (REYATAZ), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 4 Weeks to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing atazanavir in Acquired Immunodeficiency Syndrome as a file.
02

Study summary

The goal of this clinical study is to learn more about the safety and dosing of study drugs, cobicistat-boosted Atazanavir (ATV/co), cobicistat-boosted darunavir (DRV/co) and emtricitabine/tenofovir alafenamide (F/TAF), in children (age ≥ 4 weeks to \< 18 years) with HIV.

03

Conditions studied

  • Acquired Immune Deficiency Syndrome (AIDS)
  • HIV Infections

Keywords

  • Pediatrics
  • Adolescents
  • HIV
  • HIV-1
  • Treatment experienced
04

Who can participate

Ages eligible
4 Weeks to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • -1 infected, virologically suppressed males and females age ≥ 4 weeks to \< 18 years (according to requirements of enrolling Cohort).
  • Body weight at screening ≥ 25 to \< 40 kg (Cohort 2); ≥ 14 to \< 25 kg (Cohort 3); ≥ 3 to \< 25 kg (Cohort 4); ≥ 3 to \< 14 kg (Cohort 5).
  • Stable antiretroviral (ARV) regimen for a minimum of 3 months prior to the screening visit.

    • Participants enrolled prior to implementation of Amendment 7: 2 nucleoside reverse transcriptase inhibitors (NRTIs) and ritonavir-boosted atazanavir (ATV/r) once daily or ritonavir-boosted darunavir (DRV/r) once daily or twice daily.
    • Participants enrolled after the implementation of Amendment 9:

      • Cohorts 2, 3 and 4 (Group 1): 2 NRTIs plus a third agent per local prescribing guidelines. Participants will switch from their current third agent to ATV or darunavir (DRV) at Day 1. Participants taking DRV must be on once-daily dosing or must switch to once daily at or prior to Day 1. Cohort 4 (Group 1), participants may also switch their current third agent to lopinavir boosted with ritonavir (LPV/r) at Day 1. Participants will switch their NRTI backbone to emtricitabine/tenofovir alafenamide (coformulated; Descovy®) (F/TAF).
      • Cohort 4 (Groups 2 to 4) and Cohort 5 (Groups 1 to 3): 2 NRTIs plus a third agent per local prescribing guidelines or treatment naive. Participants on treatment will switch from their current third agent to ATV or LPV/r (Cohort 4 (Groups 2 to 4)), or to a third unboosted agent (Cohort 5 (Groups 1 to 3)). Participants will switch their NRTI backbone to F/TAF.
  • Participants undergoing dose modifications to their ARV regimen for growth or switching medication formulations are considered to be on a stable ARV regimen.
  • Documented plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) for ≥ 3 months preceding the screening visit:

    • Participants enrolled after the implementation of Amendment 9:

      • For Cohorts 2, 3, and 4 (Group 1), virologically suppressed ≥ 3 months preceding the screening visit: HIV-1 RNA \< 50 copies/mL on a stable regimen (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
      • For Cohorts 4 (Groups 2 to 4) and Cohort 5 (Groups 1 to 3), on an ARV regimen irrespective of plasma HIV-1 RNA copies or treatment naive; a participant is considered treatment naive, if ARVs were given for prevention of mother-to-child transmission but not for HIV treatment.
    • For virologically suppressed participants, unconfirmed virologic elevations of HIV-1 RNA ≥ 50 copies/mL (transient detectable viremia, or "blip") prior to screening are acceptable. If the lower limit of detection of the local HIV-1 RNA assay is \< 50 copies/mL (eg, \< 20 copies/mL), the plasma HIV-1 RNA level cannot exceed 50 copies/mL on 2 consecutive HIV-1 RNA tests.
  • Adequate renal function: Estimated (eGFR) ≥ 90 mL/min/1.73m2 using the Schwartz formula. If ≥ 1 year old, eGFR greater than or equal to the minimum normal value for age using the Schwartz formula. If \< 1 year old as follows:

    • Age minimum value for eGFR (mL/min/1.73 m2) > 28 days to ≤ 95 days is 30, ≥ 96 days to ≤ 6 months is 39, > 6 to \< 12 months is 49.
  • Participants must not have documented or suspected resistance to applicable study drugs including emtricitabine (Emtriva®) (FTC), TFV, ATV, DRV, or LPV. Participants \< 14 kg (Cohorts 4 (Groups 2 to 4) and 5 (Groups 1 to 3)) with M184V/I AND HIV-1 RNA \< 50 copies/mL will be allowed.
  • Positive confirmatory HIV test (confirmatory nucleic acid-based testing if \< 18 months of age).
  • Cohort 4 (Groups 2 to 4) and Cohort 5 (Groups 1 to 3): Last dose of nevirapine or efavirenz, if applicable, ≥ 14 days prior to enrollment.

Note: Other protocol defined Inclusion/Exclusion criteria do apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    Cohort 1: Part A and Part B

    Participants ages 12 to \<18 years old will receive cobicistat 150 mg with either ATV or DRV plus background regimen (BR). The BR may contain additional antiretroviral agents except for the following disallowed agents: saquinavir, indinavir, nelfinavir, double protease inhibitor (PI) regimens, raltegravir, elvitegravir, efavirenz, nevirapine, delavirdine, maraviroc, etravirine, rilpivirine, dolutegravir, and investigational antiretroviral agents.

    Drug: ATV · Drug: DRV · Drug: Cobicistat · Drug: BR

  • Experimental
    Cohort 2

    Participants aged 6 to \<12 years old and ≥25 to \<40kg will receive cobicistat 150 mg and F/TAF 200/25 mg with either ATV or DRV.

    Drug: ATV · Drug: DRV · Drug: Cobicistat · Drug: F/TAF

  • Experimental
    Cohort 3

    Participants age ≥ 2 years old will receive cobicistat 90 mg and F/TAF 120/15 mg with either ATV or DRV.

    Drug: ATV · Drug: DRV · Drug: Cobicistat · Drug: F/TAF

  • Experimental
    Cohort 4 (Group 1)

    Participants age ≥ 4 weeks old weighing 14 to \< 25 kg will receive cobicistat tablet for oral suspension (TOS) 90 mg, once daily and F/TAF TOS 120/15 mg, once daily with either ATV or DRV or lopinavir boosted by ritonavir (LPV/r). Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, minimum age and weight for DRV is ≥ 3 years and ≥ 15 kg; participants receiving LPV/r will not receive cobicistat TOS.

    Drug: ATV · Drug: DRV · Drug: LPV/r · Drug: Cobicistat TOS · Drug: F/TAF TOS

  • Experimental
    Cohort 4 (Group 2)

    Participants age ≥ 4 weeks old weighing 10 to \< 14 kg will receive cobicistat TOS 30 mg (twice daily) and F/TAF TOS 60/7.5 mg, once daily with either ATV or LPV/r. Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, respectively; participants receiving LPV/r will not receive cobicistat TOS.

    Drug: ATV · Drug: LPV/r · Drug: Cobicistat TOS · Drug: F/TAF TOS

  • Experimental
    Cohort 4 (Group 3)

    Participants age ≥ 4 weeks old weighing 6 to \< 10 kg will receive cobicistat TOS 30 mg (twice daily) and F/TAF TOS 30/3.75 mg, once daily with either ATV or LPV/r. Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, respectively; participants receiving LPV/r will not receive cobicistat TOS.

    Drug: ATV · Drug: LPV/r · Drug: Cobicistat TOS · Drug: F/TAF TOS

  • Experimental
    Cohort 4 (Group 4)

    Participants age ≥ 4 weeks old weighing 3 to \< 6 kg will receive cobicistat TOS 30 mg (twice daily) and F/TAF TOS 15/1.88 mg, once daily with either ATV or LPV/r. Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, respectively; participants receiving LPV/r will not receive cobicistat TOS.

    Drug: ATV · Drug: LPV/r · Drug: Cobicistat TOS · Drug: F/TAF TOS

  • Experimental
    Cohort 5 (Group 1)

    Participants ages ≥ 4 weeks old weighing ≥ 10 to \< 14 kg will receive F/TAF TOS 60/7.5 mg, once daily with the third unboosted drug.

    Drug: Third Unboosted Drug · Drug: F/TAF TOS

  • Experimental
    Cohort 5 (Group 2)

    Participants ages ≥ 4 weeks old weighing ≥ 6 to \< 10 kg will receive F/TAF TOS 30/3.75 mg, once daily with the third unboosted drug.

    Drug: Third Unboosted Drug · Drug: F/TAF TOS

  • Experimental
    Cohort 5 (Group 3)

    Participants ages ≥ 4 weeks old weighing ≥ 3 to \< 6 kg will receive F/TAF TOS 15/1.88 mg, once daily with the third unboosted drug.

    Drug: Third Unboosted Drug · Drug: F/TAF TOS

Interventions

  • DrugATV

    Capsules administered once daily according to dosing recommendations per product monograph

    Also known as: Reyataz®

  • DrugDRV

    Tablets administered once daily according to dosing recommendations per product monograph

    Also known as: Prezista®

  • Tablets administered orally once daily with food

    Also known as: GS-9350, Tybost®

  • DrugBR

    Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), and emtricitabine (FTC).

  • DrugF/TAF

    Drug pages: Emtricitabine · Tenofovir alafenamide

    Tablets administered orally once daily

    Also known as: Descovy®

  • DrugLPV/r

    Drug pages: Lopinavir · Ritonavir

    Solution administered orally

  • DrugThird Unboosted Drug

    ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.

  • Tablets for oral suspension

    Also known as: GS-9350, Tybost®

  • DrugF/TAF TOS

    Drug page: Emtricitabine tenofovir alafenamide

    Tablets for oral suspension

    Also known as: Descovy®

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: AUCtau of ATV, DRV, TAF, and TFV

    AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). AUCtau for ATV (Cohorts 1 Part A, 2, 3, and 4 \[Groups 2 to 4\]); DRV (Cohorts 1 Part A, 2, and 3); TAF (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 \[Groups 1 to 3\] taking F/TAF); and TFV (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 \[Groups 1 to 3\] taking F/TAF) will be reported.

    Time frame: Predose on Day 1, and postdose up to Week 48

  2. Percentage of Participants Experiencing Treatment Emergent Adverse Events (AEs) Through Week 24

    Time frame: First dose date up to Week 24 plus 30 days (Cumulative data through Week 24)

  3. Percentage of Participants Experiencing Treatment Emergent Laboratory Abnormalities Through Week 24

    Time frame: First dose date up to Week 24 plus 30 days (Cumulative data through Week 24)

Secondary outcomes

  1. PK Parameter: Ctau of ATV, DRV, COBI, FTC and TFV

    Ctau is defined as the observed drug concentration at the end of the dosing interval. Ctau for ATV (cohorts 1, 2, 3, and 4 (Groups 2 to 4)), DRV (cohorts 1, 2, and 3), COBI (except Cohort 5), FTC and TFV (cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF) will be reported.

    Time frame: Predose on Day 1, and postdose up to Week 48

  2. PK Parameter: Cmax of ATV, DRV, COBI, TAF, FTC and TFV

    Cmax is defined as the maximum observed concentration of drug. Cmax for ATV (Cohorts 1, 2, 3, and 4 \[Groups 2 to 4\]) and DRV (Cohorts 1, 2, and 3); for COBI (except Cohort 5); for TAF, FTC and TFV (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF) will be reported.

    Time frame: Predose on Day 1, and postdose up to Week 48

  3. PK Parameter: CL/F of ATV, DRV, COBI, TAF, FTC and TFV

    CL/F is defined as the apparent oral clearance following administration of the drug. CL/F for ATV (Cohorts 1, 2, 3, and 4 \[Groups 2 to 4\]) and DRV (Cohorts 1, 2, and 3); for COBI (except Cohort 5); for TAF, FTC and TFV (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF) will be reported.

    Time frame: Predose on Day 1, and postdose up to Week 48

  4. PK Parameter: Vz/F of COBI, TAF, FTC and TFV

    Vz/F is defined as the apparent volume of distribution of the drug. Vz/F for COBI (Except Cohort 5); for TAF (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF); for FTC and TFV (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF) will be reported.

    Time frame: Predose on Day 1, and postdose up to Week 48

  5. PK Parameter: AUCtau of COBI and FTC

    AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). AUCtau for COBI (Except Cohort 5) and FTC will be reported.

    Time frame: Predose on Day 1, and postdose up to Week 48

  6. PK Parameter: AUClast of TAF, FTC and TFV

    AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. AUClast for TAF (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF); for FTC and TFV (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF) will be reported.

    Time frame: Predose on Day 1, and postdose up to Week 48

  7. PK Parameter: Clast of TAF

    Clast is defined as the the last observed quantifiable concentration of the drug in plasma. Clast for TAF (Cohorts 2, 3, 4 \[Groups 1 to 4\] and 5 taking F/TAF) will be reported.

    Time frame: Predose on Day 1, and postdose up to Week 48

  8. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Time frame: First dose date up to Week 48 plus 30 days (Cumulative data through Week 48)

  9. Percentage of Participants Experiencing Clinically Significant Changes in Safety Laboratory Values

    Time frame: First dose date up to Week 48 plus 30 days (Cumulative data through Week 48)

  10. Percentage of Participants with HIV-1 RNA < 50 Copies/mL at Week 24 and as Defined by the US FDA-defined Snapshot Algorithm

    Time frame: Week 24

  11. Percentage of Participants with HIV-1 RNA < 50 Copies/mL at Week 48 and as Defined by the US FDA-defined Snapshot Algorithm

    Time frame: Week 48

  12. Change from Baseline in CD4+ Cell Counts (cells/μL) at Week 24

    Time frame: Baseline, Week 24

  13. Change from Baseline in CD4+ Cell Counts (cells/μL) at Week 48

    Time frame: Baseline, Week 48

  14. Change from Baseline in Percentage of CD4+ Cells at Week 24

    Time frame: Baseline, Week 24

  15. Change from Baseline in Percentage of CD4+ Cells at Week 48

    Time frame: Baseline, Week 48

  16. Acceptability of COBI and F/TAF as Measured by Palatability Score

    Time frame: Week 48

07

Study locations

23 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2014 to primary completion in Jun 2025, 136 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2013
First posted
Dec 20, 2013
StartActual
Jan 16, 2014
Primary completionActual
Jun 13, 2025
CompletionEst.
Mar 2027
Results delay requested
Mar 17, 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02016924
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Dec 20, 2013
Start date
Jan 16, 2014
Primary completion
Jun 13, 2025
Completion
Mar 2027 (estimated)
Last update
Apr 21, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atazanavir · Darunavir · Cobicistat · Emtricitabine · Tenofovir alafenamide · Emtricitabine tenofovir alafenamide

Start the discussion